The 52nd Annual Meeting of the Japanese Society of Toxicology
To Participants
Notice of changes to the Program & Abstract Book

We would like to inform you that the following changes have been made after printing the Program & Abstract Book.

	Lunchtime Seminar L1-7		
Applicable page	10, 162		
Before the change			After the change
Sponsored by : Axcelead Drug Discovery Partners, Inc. / Future Peak, Inc.		⇒	Sponsored by : Axcelead Drug Discovery Partners, Inc. / **Mediford Corporation**

	Workshop 2		
Applicable page	60-61, S72		
Before the change			After the change
W2-1 Izuru MIYAWAKI 9:15-9:21 W2-2 Naoko TANAKA 9:21-9:42 W2-3 Takafumi YOTSUMOTO 9:42-10:03 W2-4 Takeshi WATANABE 10:03-10:24 W2-5 Sho AKAI 10:24-10:45		⇒	W2-1 Izuru MIYAWAKI **9:15-9:23** W2-2 Naoko TANAKA **9:23-9:51** W2-3 Takafumi YOTSUMOTO **9:51-10:14** W2-4 Takeshi WATANABE **10:14-10:37** **Plenary Q&A 10:37-10:45**

	Candidates for the Excellent Presentation Award(Oral・Poster) P-126E		
Applicable page	77, 105, S153		
Before the change			After the change
P-126E Application of Drug-Induced Liver Injury (DILI) Prediction Model Using Integrated Datasets and Machine Learning Approaches ○Taro KAKUZAKI Research Division, Chugai Pharmaceutical, Co., Ltd.		⇒	**Withdrawal**
Applicable page	11, 77		
＜Session time＞ Before the change			After the change
Candidates for the Excellent Presentation Award (Oral) 4 15:04 - 15:58		⇒	**15:04 - 15:52** ***The individual presentation times for P-128E to P-139E have been moved forward by one abstract.**

	Poster Session P-288		
Applicable page	128, S218		
Before the change			After the change
P-288 An exploratory toxicity study focusing on the metabolite ○Sanae OMI Eisai Co., Ltd.		⇒	**Withdrawal**

	Poster Session P-318		
Applicable page	133, S230		
Before the change			After the change
[2]Division of Advanced Predictive Research, Korea Institute of Toxicology		⇒	**[2]Division of Next Generation Non-Clinical Research**

	Lunchtime Seminar L3-5		
Applicable page	165		
Before the change			After the change
Targeted Protein Degradation of the Androgen Receptor by ARCC-4 and ARD-2128: Proteomic and Therapeu tic Potential in AR-driven Cancers		⇒	**①Targeted Protein Degradation of the Androgen Receptor by ARCC-4 and ARD-2128: Proteomic and Therapeutic Potential in AR-driven Cancers** Speaker：Chun-Yao Lee, Ph.D.(Managing Director, Eurofins Panlabs Discovery Services Taiwan) **②Evaluation of Drugs in Assays to Address Neuroinflammation, Cytotoxicity, Safety, and Broader Biological Effects** Speaker：Alastair J. King, Ph.D (Head of Biology, Eurofins Discovery)

	Poster Session P-237		
Applicable page	S198		
Before the change			After the change
P-237 Subacute exposure of 2, 2′ , 4, 4′ -tetrabromodiphenyl ether induced liver injury by inhibiting mitochondrial autophagy and increasing NLRP3 inflammasome in mice ○Shuhua XI China Medical University, School of Public Health		⇒	**Withdrawal**